These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 31748278)
21. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P; Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079 [TBL] [Abstract][Full Text] [Related]
22. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer. Karsten M; Stempel M; Radosa J; Patil S; King TA Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863 [TBL] [Abstract][Full Text] [Related]
23. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898 [TBL] [Abstract][Full Text] [Related]
24. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results. Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662 [TBL] [Abstract][Full Text] [Related]
25. Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. Yang DD; Buscariollo DL; Cronin AM; Weng S; Hughes ME; Bleicher RJ; Cohen AL; Javid SH; Edge SB; Moy B; Niland JC; Wolff AC; Hassett MJ; Punglia RS Radiat Oncol; 2020 Aug; 15(1):198. PubMed ID: 32799886 [TBL] [Abstract][Full Text] [Related]
26. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT Schildgen V; Warm M; Brockmann M; Schildgen O Sci Rep; 2019 Dec; 9(1):20266. PubMed ID: 31889145 [TBL] [Abstract][Full Text] [Related]
27. [Application of 21-gene recurrence risk score in patients with breast cancer]. Chen Q; Shen HX; Wang YL; Zhao J; Ma JF; Wang SQ; Fu PF Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):678-684. PubMed ID: 38955698 [No Abstract] [Full Text] [Related]
28. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population. Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027 [TBL] [Abstract][Full Text] [Related]
29. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer. Morales Murillo S; Gasol Cudos A; Veas Rodriguez J; Canosa Morales C; Melé Olivé J; Vilardell Villellas F; Sanchez Guzman DR; Iglesias Martínez E; Salud Salvia A Breast; 2021 Apr; 56():35-41. PubMed ID: 33601299 [TBL] [Abstract][Full Text] [Related]
30. 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. Turashvili G; Chou JF; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY Breast Cancer Res Treat; 2017 Nov; 166(1):69-76. PubMed ID: 28702894 [TBL] [Abstract][Full Text] [Related]
31. 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer. Chen XH; Zhang WW; Wang J; Sun JY; Li FY; He ZY; Wu SG Biomark Med; 2019 Feb; 13(2):83-93. PubMed ID: 30565472 [TBL] [Abstract][Full Text] [Related]
32. Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time. Williams AD; Reyes SA; Arlow RL; Tchou J; De La Cruz LM Ann Surg Oncol; 2018 Oct; 25(10):2875-2883. PubMed ID: 29959613 [TBL] [Abstract][Full Text] [Related]
33. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer. Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843 [TBL] [Abstract][Full Text] [Related]
34. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717 [TBL] [Abstract][Full Text] [Related]
35. The Added Prognostic Value of Oncotype Recurrence Score to AJCC Prognostic Staging System in Stage III ER+/HER2- Breast Cancer. Wang M; Zhang M; Chen H Adv Ther; 2023 Sep; 40(9):3912-3925. PubMed ID: 37382865 [TBL] [Abstract][Full Text] [Related]
36. Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study. Buus R; Sestak I; Barron S; Loughman T; Fender B; Ruiz CL; Dynoodt P; Wang CA; O'Leary D; Gallagher WM; Dowsett M; Cuzick J Clin Cancer Res; 2020 Feb; 26(3):623-631. PubMed ID: 31641007 [TBL] [Abstract][Full Text] [Related]
37. Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage. Yu-Qing Y; Lei W; Mei-Ling H; Jing-Jing X; Mei-Chen W; Jiang W; Jun-Sheng H; Rui L; Nan-Lin L Exp Mol Pathol; 2019 Jun; 108():150-155. PubMed ID: 31026440 [TBL] [Abstract][Full Text] [Related]
38. 21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer. Kizy S; Altman AM; Marmor S; Denbo JW; Jensen EH; Tuttle TM; Hui JYC J Geriatr Oncol; 2019 Mar; 10(2):322-329. PubMed ID: 30093354 [TBL] [Abstract][Full Text] [Related]
39. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx. Sughayer MA; Alhassoon S; Sughayer HM Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992 [TBL] [Abstract][Full Text] [Related]
40. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up. Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]